Holly Schachner, MD is our SVP, Clinical Development. Most recently, Holly was Chief Medical Officer at Double Rainbow Biosciences, a preclinical stage platform biotech company. Prior, Holly was SVP, Clinical Science at MyoKardia, a clinical-stage biopharmaceutical company focused on cardiovascular therapies that was acquired by BMS in 2020. Previously, Holly was Chief Medical Officer, Specialty Medicine at Allergan, where she led global therapeutic areas including Women’s Health, Infectious Disease, IBD, Metabolism and NASH in various stages of development. In addition, Holly was North America Medical Head for the Diabetes Cardiovascular (DCV) Business Unit at Sanofi where she led launch preparedness for several pipeline products, including PCSK-9i. She served simultaneously as U.S. Medical Chair on the US Leadership team and served on the board of the Sanofi Foundation for North America. Earlier in her career, Holly held medical leadership positions at Bayer Diabetes Care, Pfizer, Inc., and at Columbia University.
In addition, Holly is currently a Board member at Applied Molecular Transport and a Scientific Advisory to EnCellin.
Holly holds a Doctor of Medicine (MD) degree from the State University of New York, Stony Brook and a bachelor’s degree from the University of Michigan. She completed her Pediatric Residency and Pediatric Endocrinology Fellowship at Mount Sinai Medical Center in New York City.